Top Markets
#1 Black Phoenix Black Phoenix +734.11%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.07%
#3 TENDIES TENDIES +23.35%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +18.05%
#5 Verus Coin Verus Coin +13.88%
#6 THORChain THORChain +13.44%
#7 MetaDAO MetaDAO +11.43%
#8 Biconomy Biconomy +11.09%
#9 The Bitcoin Bull The Bitcoin Bull +10.31%
#10 THORChain Yield THORChain Yield +9.46%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Keymed Biosciences Inc. Keymed Biosciences Inc.

Keymed Biosciences Inc.

2162
Rank in Stocks #5197
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China... Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
Share Price
$9.85
Market Cap
$2.90B
Change (1 day)
-3.87%
Change (1 year)
15.34%
Country
CN
Trade Keymed Biosciences Inc. (2162)

Category

Healthcare
P/E ratio for Keymed Biosciences Inc. (2162)
P/E ratio as of 2026 TTM: 0
According to Keymed Biosciences Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Keymed Biosciences Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.